EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up

Thomas Powles iD, Se Hoon Park iD, Claudia Caserta, Begoña P Valderrama, Howard Gurney iD, Anders Ullén, Yohann Loriot iD, Srikala S Sridhar iD, Cora N Sternberg iD, Joaquim Bellmunt iD, Jeanny B Aragon-Ching iD, Jing Wang und 4 weitere

Journal of Clinical Oncology · 01.07.2023 · 41 (19) · 3486-3492

DOI: 10.1200/jco.22.01792 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.07.2023. Verfasst von Thomas Powles und 15 weiteren Autor:innen. Beteiligte Einrichtung: Barts Cancer Institute, Experimental Cancer Medicine Center, Queen Mary University of London, St Bartholomew's Hospital, London, United Kingdom. Hauptthemen laut MEDLINE: Carcinoma, Transitional Cell, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 220-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned coprimary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. Initial results from the phase III JAVELIN Bladder 100 trial (ClinicalTrials.gov identifier: NCT02603432 ) showed that avelumab first-line (1L) maintenance plus best supportive care (BSC) significantly prolonged overall survival (OS) and progression-free survival (PFS) versus BSC alone in patients with advanced urothelial carcinoma (aUC) who were progression-free after 1L platinum-containing chemotherapy. Avelumab 1L maintenance treatment is now a standard of care for aUC. Here, we report updated data with ≥ 2 years of follow-up in all patients, including OS (primary end point), PFS, safety, and additional novel analyses. Patients were randomly assigned 1:1 to receive avelumab plus BSC (n = 350) or BSC alone (n = 350). At data cutoff (June 4, 2021), median follow-up was 38.0 months and 39.6 months, respectively; 67 patients (19.5%) had received ≥2 years of avelumab treatment. OS remained longer with avelumab plus BSC versus BSC alone in all patients (hazard ratio, 0.76 [95% CI, 0.63 to 0.91]; 2-sided P = .0036). Investigator-assessed PFS analyses also favored avelumab. Longer-term safety was consistent with previous analyses; no new safety signals were identified with longer treatment duration. In conclusion, longer-term follow-up continues to show clinically meaningful efficacy benefits with avelumab 1L maintenance plus BSC versus BSC alone in patients with aUC. An interactive visualization of data reported in this article is available.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Transitional CellUrinary Bladder NeoplasmsHumansFollow-Up StudiesUrinary BladderAntineoplastic Combined Chemotherapy ProtocolsAntibodies, Monoclonal, Humanized

Substanzen

avelumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Barts Cancer Institute, Experimental Cancer Medicine Center, Queen Mary University of London, St Bartholomew's Hospital, London, United Kingdom.
  • Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Medical Oncology Unit, Azienda Ospedaliera S. Maria, Terni, Italy.
  • Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
  • Department of Clinical Medicine, Macquarie University, Sydney, New South Wales, Australia.
  • Department of Pelvic Cancer, Genitourinary Oncology Unit, Karolinska University Hospital, Solna, Sweden.

ORCID-Profile: Thomas Powles, Se Hoon Park, Howard Gurney, Yohann Loriot, Srikala S Sridhar, Cora N Sternberg, Joaquim Bellmunt, Jeanny B Aragon-Ching, Bo Huang, Petros Grivas

Zitieren

APA

Powles, T., Park, S. H., Caserta, C., Valderrama, B. P., Gurney, H., Ullén, A., Loriot, Y., Sridhar, S. S., Sternberg, C. N., Bellmunt, J., Aragon-Ching, J. B., Wang, J., Huang, B., Laliberte, R. J., di Pietro, A., & Grivas, P. (2023). Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up. Journal of Clinical Oncology, 41(19), 3486-3492. https://doi.org/10.1200/jco.22.01792

Vancouver

Powles T, Park SH, Caserta C, Valderrama BP, Gurney H, Ullén A, et al. Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up. Journal of Clinical Oncology. 2023;41(19):3486-3492. doi:10.1200/jco.22.01792

BibTeX
@article{Powles2023,
  author = {Powles, Thomas and Park, Se Hoon and Caserta, Claudia and Valderrama, Begoña P and Gurney, Howard and Ullén, Anders and Loriot, Yohann and Sridhar, Srikala S and Sternberg, Cora N and Bellmunt, Joaquim and Aragon-Ching, Jeanny B and Wang, Jing and Huang, Bo and Laliberte, Robert J and di Pietro, Alessandra and Grivas, Petros},
  title = {Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  volume = {41},
  number = {19},
  pages = {3486--3492},
  doi = {10.1200/jco.22.01792}
}
Kostenlos starten →